TipRanks
Cullinan Management (CGEM)
NASDAQ:CGEM
US Market
CGEM
Cullinan Management
RESEARCH TOOLSreports
Want to see CGEM full AI Analyst Report?

Cullinan Management (CGEM) Stock News & Sentiment

371 Followers
Cullinan Management Advances NDA for Zipalertinib Combination
Premium
Company Announcements
Cullinan Management Advances NDA for Zipalertinib Combination
3d ago
8K
CGEM
Matt Phipps Reiterates Buy on Cullinan Oncology, Citing Pullback-Driven Upside and Upcoming Q4 Clinical Data Catalysts
Premium
Ratings
Matt Phipps Reiterates Buy on Cullinan Oncology, Citing Pullback-Driven Upside and Upcoming Q4 Clinical Data Catalysts
11d ago
CGEM
Cullinan Management Highlights Q4 T Cell Engager Milestones
Premium
Company Announcements
Cullinan Management Highlights Q4 T Cell Engager Milestones
11d ago
8K
CGEM
Cullinan Maintained at Buy on Zipalertinib Strength, Unchanged $33 Price Target
Premium
Ratings
Cullinan Maintained at Buy on Zipalertinib Strength, Unchanged $33 Price Target
20d ago
CGEM
Cullinan Highlights Positive Phase 3 Lung Cancer Results
Premium
Company Announcements
Cullinan Highlights Positive Phase 3 Lung Cancer Results
21d ago
8K
CGEM
Matt Phipps Reiterates Buy on Cullinan After Strong Phase III REZILIENT3 Data for Zipalertinib in First-Line EGFR Exon 20–Mutant NSCLC
Premium
Ratings
Matt Phipps Reiterates Buy on Cullinan After Strong Phase III REZILIENT3 Data for Zipalertinib in First-Line EGFR Exon 20–Mutant NSCLC
21d ago
CGEM
Boris Peaker Reiterates Buy on Cullinan, Maintains $36 Price Target on Strong Zipalertinib Data and CLN-978-Driven Valuation
Premium
Ratings
Boris Peaker Reiterates Buy on Cullinan, Maintains $36 Price Target on Strong Zipalertinib Data and CLN-978-Driven Valuation
21d ago
CGEM
More CGEM News >

CGEM News on the Web

Cullinan Management Advances NDA for Zipalertinib Combination
TipRanks News
Neutral
Matt Phipps Reiterates Buy on Cullinan Oncology, Citing Pullback-Driven Upside and Upcoming Q4 Clinical Data Catalysts
TipRanks News
Bullish
Cullinan Therapeutics (CGEM) Reports a Six-Month PFS Gain. Can it Justify Higher Toxicity?
Insider Monkey
Neutral
Cullinan Therapeutics, Inc. to Host Virtual Analyst and Investor Event Transcript
GuruFocus News
Neutral
Cullinan Highlights Positive Phase 3 Lung Cancer Results
TipRanks News
Neutral
Cullinan's Zipalertinib Plus Chemotherapy Extends PFS By 6 Months In EGFR Ex20+ Lung Cancer
rttnews
Bullish
Cullinan, Taiho announce Phase 3 REZILIENT3 trial met primary endpoint
TipRanks News
Bullish
Cullinan Therapeutics To Present Phase 3 REZILIENT3 Data At IASLC 2026 On Sunday
rttnews
Bullish

News Score - Last 7 Days

Very Positive
CGEM
Sector Average
Media Buzz
This Week6 articles
Weekly Average6 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CGEM’s Media Buzz Sentiment?
6 articles about CGEM were published this week. In an average week, 6 articles are published.
    What is CGEM’s weekly average amount of articles?
    In an average week, 6 articles about CGEM are published.
      What is CGEM’s News Sentiment?
      100% of articles about CGEM were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        BAYRYBayer
        ABTAbbott Laboratories
        INCYIncyte
        SMMTSummit Therapeutics
        CRVOCervoMed
        Showing the stocks with the most bullish news sentiment over the past week